Search research articles
Contact Us
Filters
Showing results (251-260 of 346) with videos related to
Page
of 35
Sort By:
Cancer
|
June 17, 2021
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Koji Sasaki, Hagop M Kantarjian, Kiyomi Morita, et al.
Blood
|
July 25, 2022
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis
Armin Ghobadi, Michael Slade, Hagop Kantarjian, et al.
Blood Neoplasia
|
September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Leukemia & Lymphoma
|
September 21, 2020
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis
Musa Yilmaz, Hagop M Kantarjian, Gokce Toruner, et al.
Blood Advances
|
March 20, 2026
Mutations in Isocitrate Dehydrogenase Portend a Poor Prognosis in Adult Patients with Acute Lymphoblastic Leukemia
Hannah Goulart, Nicholas J Short, Gautam Borthakur, et al.
Blood Cancer Journal
|
May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
Musa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
The Lancet. Haematology
|
April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib
Kelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
Leukemia & Lymphoma
|
July 19, 2017
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
Nicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
American Journal of Hematology
|
February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial
Issa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Page
of 35
Search research articles
Search
Showing results (251-260 of 346) with videos related to
Sort By:
Page
of 35
Cancer
|
June 17, 2021
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Koji Sasaki, Hagop M Kantarjian, Kiyomi Morita, et al.
Blood
|
July 25, 2022
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis
Armin Ghobadi, Michael Slade, Hagop Kantarjian, et al.
Blood Neoplasia
|
September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Leukemia & Lymphoma
|
September 21, 2020
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis
Musa Yilmaz, Hagop M Kantarjian, Gokce Toruner, et al.
Blood Advances
|
March 20, 2026
Mutations in Isocitrate Dehydrogenase Portend a Poor Prognosis in Adult Patients with Acute Lymphoblastic Leukemia
Hannah Goulart, Nicholas J Short, Gautam Borthakur, et al.
Blood Cancer Journal
|
May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
Musa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
The Lancet. Haematology
|
April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib
Kelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
Leukemia & Lymphoma
|
July 19, 2017
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
Nicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
American Journal of Hematology
|
February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial
Issa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Page
of 35